Melaleuca Pharmaceutical Board Resolution to Issue First Overseas Unsecured Convertible Bonds

1. Date of Board Resolution: 115/06/11 2. Name [XX Company's Xth (Secured/Unsecured) Bond]: Melaleuca Pharmaceutical Co., Ltd. First Overseas Unsecured Convertible Bonds 3. Whether to adopt a shelf registration for bond issuance (Yes/No): No 4. Total Issuance Amount: Tentatively capped at USD 300 million. 5. Face Value per Bond: Tentatively set at USD 200,000 or an integer multiple thereof. 6. Issue Price: Issued at 100% of face value. 7. Term: Tentatively set at five years. 8. Interest Rate: Tentative coupon rate is 0% per annum. 9. Type, Name, Amount, and Covenants of Collateral: Not applicable 10. Use of Proceeds and Utilization Plan: Repayment of bank loans. 11. Underwriting Method: These bonds will be publicly offered overseas in accordance with the laws and regulations of the sales region. 12. Bond Trustee: To be determined 13. Underwriting or Selling Agent: Lead Underwriter (Overseas): Goldman Sachs International Lead Underwriter (Domestic): Yuanta Securities Co., Ltd. 14. Guarantor: Not applicable 15. Paying Agent: To be determined 16. Certifying Institution: Not applicable 17. If convertible into shares, conversion method: Authorized to be handled by the Chairman or their designee, who will have full discretion to process it based on market conditions and actual needs at the time of actual issuance. 18. Put Option Conditions: Authorized to be handled by the Chairman or their designee, who will have full discretion to process it based on market conditions and actual needs at the time of actual issuance. 19. Call Option Conditions: Authorized to be handled by the Chairman or their designee, who will have full discretion to process it based on market conditions and actual needs at the time of actual issuance. 20. Conversion/Exchange/Subscription Basis Date (if applicable): Authorized to be handled by the Chairman or their designee, who will have full discretion to process it based on market conditions and actual needs at the time of actual issuance. 21. Potential Dilution of Equity (if convertible, exchangeable, or subscribable): Depends on the conversion premium rate at the time of actual issuance. 22. Reasonableness and Necessity of Fundraising After Cash Capital Reduction (Applicable if cash capital reduction was conducted in the fundraising year or the preceding year): Not applicable 23. Other Matters to be Notified: Important matters concerning these bonds, including the actual issue price, issuance terms, actual total issuance amount, planned projects, progress of fund utilization, expected benefits, issuance and conversion methods for overseas unsecured convertible bonds, conversion price, listing location, and all other matters related to these bonds, may be amended or adjusted in the future due to instructions from regulatory authorities, operational assessments, changes in laws, or objective environmental needs. The Chairman or their designee is authorized to handle all such matters on behalf of the company with full discretion based on market conditions and actual needs.